[R01] Protein O' Mannosylation as a therapeutic vulnerability in KIAA1549-BRAF-driven pediatric low-grade glioma
Ente: National Cancer Institute
Scadenza: 2031-05-31
Importo max: $721,653
Paese: US
Descrizione
Abstract
Pediatric low-grade gliomas (pLGGs) are the most frequent solid tumor of childhood and include Pilocytic
Astrocytomas (PAs). Approximately 75% of PAs result from a single driver event: a rearrangement between
BRAF and the uncharacterized protein KIAA1549. The KIAA1549-BRAF fusion protein dr
Settori: National Cancer Institute
Registrati gratis su Bandolo per trovare bandi compatibili con la tua azienda.